Positive-Strand RNA Viral RdRps: From Structure Conservation and Activity Assay to Drug Development.

Abstract readReview

In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Siyuan ZhaoCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.ORCID 0009-0006-5759-1456

Ziyu LinCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.

Minglian WangCollege of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, China.ORCID 0000-0001-9378-3881

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Positive-strand RNA viruses represented by SARS-CoV-2 and DENV spread globally with high infectivity and frequent mutations, posing a severe threat to human health. However, specific and effective antiviral drugs remain limited. RNA-dependent RNA polymerase (RdRp) plays a critical role in the genome replication of RNA viruses and shows high structural conservation. No homologous protein exists in human cells, making RdRp an effective, safe, and broad-spectrum antiviral target. Therefore, establishing an RdRp activity assay for drug development based on its mechanism is of great significance. This paper summarizes the structural characteristics of RdRp and the methods for constructing RdRp activity assay, especially for cell-free activity assay. In addition, several reported RdRp inhibitors and their pharmaceutical progress are also reviewed, aiming to provide a reference for the development of novel antiviral drugs targeting RdRp.

Indexed as

Antiviral AgentsDrug DevelopmentPositive-Strand RNA VirusesRNA-Dependent RNA PolymeraseHumansRNA ReplicationSARS-CoV-2Virus ReplicationAntiviral AgentsRNA-Dependent RNA Polymerasepositive-stranded RNA virusRdRp assayRdRp inhibitorRNA-dependent RNA polymerase (RdRp)

Identifiers

PMID42357443

DOI10.3390/molecules31122044

PMCPMC13306062

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.